Skip to main content
NewslettersWatchlist

Aligos Therapeutics Inc(ALGS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.6706
Day High0.7245
Open:0.6800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Set to Open Higher as Investors Await Powell Speech, Debt Ceiling Optimism Lifts Sentiment
Globe Newswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
Globe Newswire
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
Globe Newswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
Globe Newswire
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Globe Newswire
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
Globe Newswire
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
Globe Newswire
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
Business Wire
ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm
Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
Globe Newswire
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
Motley Fool
Why Aligos Therapeutics Stock Crumbled Today
Globe Newswire
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
Globe Newswire
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Globe Newswire
Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021
Globe Newswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
Globe Newswire
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
Globe NewsWire
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
Globe NewsWire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
Globe NewsWire
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
Globe NewsWire
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
Globe NewsWire
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
Globe NewsWire
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver
Globe NewsWire
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
Globe NewsWire
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
Globe NewsWire
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Globe NewsWire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
Globe NewsWire
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
Globe NewsWire
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
Globe NewsWire
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

Profile

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.